Lv3
340 积分 2025-07-11 加入
Inotuzumab ozogamicin in the treatment of B-cell acute lymphoblastic leukemia
6个月前
已完结
Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival
6个月前
已完结
Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy
6个月前
已完结
Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia
6个月前
已完结
Bispecific antibodies engage T cells for antitumor immunotherapy
6个月前
已完结
Bispecific antibodies in acute lymphoblastic leukemia therapy
1年前
已完结
Antipsychotic Drugs and Cognitive Function
1年前
已完结
皖公网安备34019202002308
